Glenmark Pharma launches Zita DM in India for type 2 diabetes Co-morbidities of adults

Mumbai: Pharma majorGlenmark Pharma announced onWednesday that it has launchedin India the first tripledrug fixeddosecombination (FDC) of thewidely used Teneligliptin withDapagliflozin and Metformin.This FDC has been launchedunder the brand name Zita DM,and it contains the DPP4inhibitor, Teneligliptin (20mg),the SGLT2 inhibitor,Dapagliflozin (10mg), andMetformin SR (500mg/1000mg)in a fixed dose. It must be takenonce daily, under prescription, toimprove glycemic control inpatients with type 2 diabetes. Onthe occasion of the launch, Alok
Malik, President and BusinessHead, India Formulations,Glenmark Pharma, stated, “Indiahas the second-largest diabeticpopulation in the world, andType 2 diabetic patients hereoften face issues of uncontrolled
hemoglobin A1C (HbA1Ci), betacell dysfunction, which impairsinsulin secretion, along with
other co-morbidities like weightgain. Diabetes management,therefore, becomes difficult forthese patients and a challenge forhealthcare providers. Being aleader in treating diabetes, we areproud to introduce Zita DM, a
novel and affordable anti-diabeticdrug that helps improve glycemiccontrol among adult patients
with high HbA1c and other comorbiditieswhile also reducingmajor renal and cardiac adverse
events. With this robust profile,we are positive Zita DM willfacilitate patient adherence tochronic diabetes treatments.”Glenmark’s Zita portfolio ofmedicines has been benefitingaround 1.75 million Type 2
diabetic patients annually inIndia. With the launch of ZitaDM, Zita the mostcomprehensive gliptin range now
holds promise of helping Type 2diabetic patients at every stageof their treatment. According to
IQVIA sales data for the 12-month period ending August2023 (MAT August 2023), themarket for oral anti-diabetic
drugs in India is estimated to beRs 12,522 crore.

About Post Author